Document Detail


Ventricular tachycardia late after repair of congenital heart disease: efficacy of combination therapy with radiofrequency catheter ablation and class III antiarrhythmic agents and long-term outcome.
MedLine Citation:
PMID:  16580423     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This study investigated the treatment of ventricular tachycardia (VT) after repair of tetralogy of Fallot or double outlet of the right ventricle. BACKGROUND: The ideal antiarrhythmic therapy for VT in patients after repair of congenital heart disease, especially without left ventricular dysfunction, has not yet been established. METHODS: Seven consecutive patients (2 women and 5 men) with stable monomorphic sustained VT were investigated. The mean age was 25 +/- 7 years (range, 16-35 years). Four patients had undergone surgical repair of tetralogy of Fallot, and 3 had surgical correction of double outlet of the right ventricle at the mean age of 18 +/- 7 years (range, 9-27 years) before documentation of the arrhythmia. RESULTS: The mean ejection fraction of the left ventricle was 60% +/- 8% (range, 50-72). Fourteen sustained monomorphic VTs were induced in 7 patients using programmed electrical stimulation. The mean cycle length of tachycardia was 346 +/- 77 milliseconds (range, 260-480 seconds). The site of the surgical correction of the right ventricle was associated with the origin of VT in all patients. Radiofrequency catheter ablation was attempted in 8 VTs in 7 patients: 7 clinical and 1 nonclinical VTs. In 6 patients, class III antarrhythmic agents were added because VT remained inducible after ablation. During a follow-up of 61 +/- 29 months (range, 15-110 months), there were no recurrences of VT. CONCLUSION: In patients with drug-refractory VT originating from the right ventricle late after congenital heart disease, and when their left ventricular function do not deteriorate, combined therapy for radiofrequency catheter ablation with class III antiarrhythmic agents might effective and should be considered as a therapeutic option.
Authors:
Hiroshi Furushima; Masaomi Chinushi; Hirotaka Sugiura; Satoru Komura; Yasutaka Tanabe; Hiroshi Watanabe; Takashi Washizuka; Yoshifusa Aizawa
Related Documents :
7731343 - Clofazimine induced cardiotoxicity--a case report.
19269983 - 'time to effect' during cryomapping: a parameter related to the long-term success of ac...
8816643 - Osteoarthrosis of the atlanto-axial joints. long-term follow-up after treatment with ar...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of electrocardiology     Volume:  39     ISSN:  0022-0736     ISO Abbreviation:  J Electrocardiol     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-03     Completed Date:  2006-09-28     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0153605     Medline TA:  J Electrocardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  219-24     Citation Subset:  IM    
Affiliation:
The First Department of Internal Medicine, Niigata University School of Medicine, Niigata 951-8510, Japan. chimiri@med.niigata-u.ac-jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anti-Arrhythmia Agents / therapeutic use*
Catheter Ablation*
Combined Modality Therapy
Electrocardiography
Female
Heart Defects, Congenital / complications*,  surgery
Humans
Male
Tachycardia, Ventricular / etiology,  therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Arrhythmia Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow.
Next Document:  P-wave morphology correlation with left atrial volumes assessed by 2-dimensional echocardiography.